trending Market Intelligence /marketintelligence/en/news-insights/trending/ZHA4RAozdNHm4sZrrFdLSA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

US district court rejects Teva patent infringement claims

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


US district court rejects Teva patent infringement claims

The U.S. District Court for the District of Delaware rejected Teva Pharmaceutical Industries Ltd.'s patent infringement claims against the generic versions of its multiple sclerosis drug Copaxone.

The court invalidated all asserted claims against five of the six drug applications for a generic version of Copaxone. Mylan NV and Sandoz Inc. are two of the companies seeking to sell a generic version of Copaxone.

Teva plans to appeal the decision.